Cytokine Storms in Cancer and COVID-19.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
09 11 2020
09 11 2020
Historique:
pubmed:
12
10
2020
medline:
1
12
2020
entrez:
11
10
2020
Statut:
ppublish
Résumé
During the COVID-19 pandemic, research on "cytokine storms" has been reinvigorated in the field of infectious disease, but it also has particular relevance to cancer research. Interleukin-6 (IL-6) has emerged as a key component of the immune response to SARS-CoV-2, such that the repurposing of anti-IL-6 therapeutics for COVID-19 is now a major line of investigation, with several ongoing clinical trials. We lay a framework for understanding the role of IL-6 in the context of cancer research and COVID-19 and suggest how lessons learned from cancer research may impact SARS-CoV-2 research and vice versa.
Identifiants
pubmed: 33038939
pii: S1535-6108(20)30493-1
doi: 10.1016/j.ccell.2020.09.019
pmc: PMC7531591
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
598-601Informations de copyright
Published by Elsevier Inc.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Nat Rev Cancer. 2016 Aug;16(8):525-37
pubmed: 27388699
Lancet Oncol. 2002 Aug;3(8):461-9
pubmed: 12147432
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Cell. 2020 Jun 25;181(7):1475-1488.e12
pubmed: 32479746
J Clin Invest. 2013 Dec;123(12):5247-57
pubmed: 24231352
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7
pubmed: 32979316
Lancet Rheumatol. 2020 Oct;2(10):e603-e612
pubmed: 32838323
Oncogene. 2006 Jul 20;25(31):4300-9
pubmed: 16518408
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Nat Rev Rheumatol. 2020 Jun;16(6):335-345
pubmed: 32327746
Cancer Cell. 2005 Mar;7(3):211-7
pubmed: 15766659